NGP 555 is a first in class small molecule for the treatment and prevention of Alzheimer’s disease. NGP 555 is an amyloid modulator showing good brain penetration in pre-clinical models and is available in capsules for once daily dosing.
The grant funds pilot clinical trials for Alzheimer’s disease. NGP has completed the Phase 1a double blind, placebo controlled, single ascending dose clinical trial with NGP 555. Five cohorts of young, healthy subjects were dosed with 25 mg – 300 mg.
All doses were safe and well-tolerated with dose-dependent plasma exposure. The 14-day Phase 1b multiple ascending dose clinical trial is expected to begin next month.
NGP 555, a proprietary "first in class" molecule for the treatment/prevention of Alzheimer’s disease, is a gamma-secretase modulator targeting the ?-secretase complex, a key enzyme in the amyloid pathway.
The compound has excellent brain penetration and is devoid of side-effects seen with other potential amyloid therapies such as gamma-secretase inhibitors and monoclonal antibodies.
Efficacy studies in animals showed beneficial and chronic effects on amyloid biomarkers, pathology and cognition while lacking the side effects of other compounds and mechanisms for preventing Alzheimer’s disease.
Based on these studies, this compound is expected to prevent the formation of Aß42 and the deposition of amyloid plaques in the human brain, thereby precluding neuronal cell death and the dementia associated with AD.